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Abstract

Nicotinic acetylcholine receptors (nAChRs) play a fundamental role in nervous signal transmission, therefore
various antagonists and agonists are highly desired to explore the structure and function of nAChRs. Recently,
a novel dimeric αD-conotoxin GeXXA was identified to inhibit nAChRs by binding at the top surface of the
receptors, and the monomeric C-terminal domain (CTD) of αD-GeXXA retains some inhibitory activity. In
this study, the internal dimeric N-terminal domain (NTD) of this conopeptide was further investigated. We
first developed a regio-selective protection strategy to chemically prepare the anti-parallel dimeric NTD, and
found that the isolated NTD part of GeXXA possesses the nAChR-inhibitory activity, the subtypedependence of which implies a preferred binding of NTD to the β subunits of nAChR. Deletion of the NTD
N-terminal residues did not affect the activity of NTD, indicating that the N-terminus is not involved in the
interaction with nAChRs. By optimizing the sequence of NTD, we obtained a fully active single-chain cyclic
NTD, based on which 4 Arg residues were found to interact with nAChRs. These results demonstrate that the
NTD part of αD-GeXXA is a "lid-covering" nAChR inhibitor, displaying a novel inhibitory mechanism
distinct from other allosteric ligands of nAChRs.
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Abstract: Nicotinic acetylcholine receptors (nAChRs) play a fundamental role in nervous signal
transmission, therefore various antagonists and agonists are highly desired to explore the structure
and function of nAChRs. Recently, a novel dimeric αD-conotoxin GeXXA was identified to inhibit
nAChRs by binding at the top surface of the receptors, and the monomeric C-terminal domain (CTD)
of αD-GeXXA retains some inhibitory activity. In this study, the internal dimeric N-terminal domain
(NTD) of this conopeptide was further investigated. We first developed a regio-selective protection
strategy to chemically prepare the anti-parallel dimeric NTD, and found that the isolated NTD part
of GeXXA possesses the nAChR-inhibitory activity, the subtype-dependence of which implies a
preferred binding of NTD to the β subunits of nAChR. Deletion of the NTD N-terminal residues
did not affect the activity of NTD, indicating that the N-terminus is not involved in the interaction
with nAChRs. By optimizing the sequence of NTD, we obtained a fully active single-chain cyclic
NTD, based on which 4 Arg residues were found to interact with nAChRs. These results demonstrate
that the NTD part of αD-GeXXA is a “lid-covering” nAChR inhibitor, displaying a novel inhibitory
mechanism distinct from other allosteric ligands of nAChRs.
Keywords: nAChR; conotoxin; αD-GeXXA; NTD; lid-covering

1. Introduction
Nicotinic acetylcholine receptors (nAChRs) are a fundamental family of pentameric ligand-gated
ion channels widely distributed and expressed in the nervous system and non-neuronal cells. In the
nervous system, binding of the endogenous neurotransmitter acetylcholine (ACh) onto the nAChR
extracellular domain opens the central transmembrane cation channel, leading to depolarization of the
postsynaptic neurons or muscle fibers [1]. Dysfunctional nAChRs have been implicated in various
neuronal disorders such as Parkinson’s disease and myasthenia gravis [2–4]. In addition, as the natural
target of nicotine, nAChRs are also the main focus of clinical therapy for smoking cessation [5]. As a
consequence, numerous efforts have been made to develop nAChR ligands (agonists, antagonists,
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and modulators), both for the structural and functional understanding of nAChRs and for potential
drug development.
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made to develop nAChR ligands (agonists, antagonists, and modulators), both for the structural and
and more
recently
α-conotoxins
from the
Conus
sea drug
snails,
which bind to the endogenous ACh
functional
understanding
of nAChRs
and for
potential
development.
orthosteric binding
site [6–8]. have
In addition,
small allosteric
ligands bind
to other sites
Natural neurotoxins
long beena variety
a major of
reservoir
for the identification
of different
nAChR‐targeting
with the
most well‐studied
beingof
thethe
kraitextracellular
α‐bungarotoxin
since the the
1960ssubunit
on nAChRs
including ligands,
the pocket
beneath
the top helix
domain,
and
more
recently
α‐conotoxins
from
the
Conus
sea
snails,
which
bind
to
the
endogenous
ACh [9–11].
interface of the extracellular domain, within the ion channel, and the transmembrane domain
orthosteric binding site [6–8]. In addition, a variety of small allosteric ligands bind to other sites on
The remarkable diversity of nAChR ligand binding sites suggests that the opening of nAChRs involves
nAChRs including the pocket beneath the top helix of the extracellular domain, the subunit interface
global conformational
changes and that novel ligands with distinct binding site will potentially provide
of the extracellular domain, within the ion channel, and the transmembrane domain [9–11]. The
new understanding
on theof
structure
and function
of nAChRs.
remarkable diversity
nAChR ligand
binding sites
suggests that the opening of nAChRs involves
Conotoxins
are a mixturechanges
of peptide
produced
marine
cone site
snails,
different
global conformational
and neurotoxins
that novel ligands
with by
distinct
binding
willtargeting
potentially
provide
newneurotransmitter
understanding on the
structurein
andthe
function
of nAChRs.
ion channels
and
receptors
nervous
system [12]. Due to their remarkable
Conotoxins
arediversity,
a mixturesome
of peptide
neurotoxins
produced
by satisfying
marine conespecificity
snails, targeting
structural and
functional
conotoxin
components
have
and potency,
different ion channels and neurotransmitter receptors in the nervous system [12]. Due to their
and consequently, great potential for therapeutic applications. The first FDA-approved conotoxin is
remarkable structural and functional diversity, some conotoxin components
have satisfying
2+ channel
ω-MVIIA
(commercially
named
orgreat
Prialt),
a selective
N-type Ca
blocker
specificity
and potency,
andZinonotide
consequently,
potential
for therapeutic
applications.
The
first with
analgesicFDA‐approved
activity [13]. conotoxin
A series of
other
conotoxins
are
currently
in
the
development
pipeline
[14–17].
is ω‐MVIIA (commercially named Zinonotide or Prialt), a selective N‐type
Recently,
we described
a new
nAChR-targeting
conopeptide,
αD-conotoxin
GeXXA,
from the
Ca2+ channel
blocker with
analgesic
activity [13]. A series
of other conotoxins
are currently
in the
development
pipeline
[14–17].
venom of Conus generalis and revealed that this dimeric peptide toxin exerts its inhibitory effect by
Recently,
described
new
nAChR‐targeting
conopeptide,
αD‐conotoxin
GeXXA, from
the
binding to the
upperwesurface
of athe
nAChRs
[18]. The
crystal structure
of αD-GeXXA
reveals
that
venom of Conus generalis and revealed that this dimeric peptide toxin exerts its inhibitory effect by
this dimeric toxin is composed of two C-terminal domains (CTD) joined by an anti-parallel dimeric
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which
the possibility that the NTD part of αD-GeXXA may also contribute to the interaction with nAChRs.
raises the possibility that the NTD part of αD‐GeXXA may also contribute to the interaction with
In addition,
the orientation of αD-GeXXA when bound onto nAChRs remains elusive, which hinders
nAChRs. In addition, the orientation of αD‐GeXXA when bound onto nAChRs remains elusive,
better understanding
of its mechanism of action.
which hinders better understanding of its mechanism of action.

Figure 1. Structure of αD‐GeXXA and putative orientation when bound to nicotinic acetylcholine

Figure 1. Structure of αD-GeXXA and putative orientation when bound to nicotinic acetylcholine
receptors (nAChR). (a) Crystal structure of αD‐GeXXA (PDB 4X9Z) [18] is shown in cartoon model.
receptors (nAChR). (a) Crystal structure of αD-GeXXA (PDB 4X9Z) [18] is shown in cartoon model.
Ten disulfide bonds are shown as yellow sticks. The N‐terminal domain (NTD) part is colored cyan,
Ten disulfide
bonds
areC‐terminal
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(NTD)binding
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(b) The putative
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colored
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αD‐GeXXA
onto nAChR.
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domains of nAChR are shown. The side chains of putative binding residues, two Arg residues of
is used to
show the nAChR (pink: α4 subunit; wheat: β2 subunit). For clarity, only the extracellular
NTD and an Asp13 residue of a β2 subunit, are shown in stick model. (c) Close‐up structure of the
domains of nAChR are shown. The side chains of putative binding residues, two Arg residues of
αD‐GeXXA NTD. The terminal residues that are deleted in short NTD are colored gray. The side chains
NTD and
an Asp13
residue ofArg
a β2
subunit,
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stick model.
(c) Close-up
structure of the
of four
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residues
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are generated
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αD-GeXXA NTD. The terminal residues that are deleted in short NTD are colored gray. The side chains
of four downward-facing Arg residues are shown as sticks. Figures are generated using Pymol.
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To address these questions, we first chemically prepared αD-GeXXA NTD, and showed that it
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Using the active cNTD as template, 4 Arg residues were found to be critical for nAChR inhibitory activity.
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2.1. Preparation of αD-GeXXA NTD
2.1. Preparation of αD‐GeXXA NTD
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A regio‐protection
strategy was
utilized
to prepare
the NTD
is Cys18
homo‐dimerized
through
two anti-parallel
inter-chain disulfide
bonds
between
residues
Cys6that
and
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ensure the proper pairing of the disulfide bonds, we synthesized two differently protected peptides
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corresponding to residues 1–20 of αD‐GeXXA, with Cys18 of one peptide and Cys6 of the second
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Figure 2. Preparation of the dimeric NTD. (a) Preparation procedure of the anti‐parallel dimeric NTD

Figure 2. Preparation of the dimeric NTD. (a) Preparation procedure of the anti-parallel dimeric NTD
from single chain N6 and N18 peptides. In the sequences of N6 and N18, the residues deleted in short
from single chain N6 and N18 peptides. In the sequences of N6 and N18, the residues deleted in short
NTD are colored gray. (b) Peptide HPLC profile of each preparation step. 1: N18 peptide; 2: N6
NTD arepeptide;
colored 3:
gray.
(b) Peptide HPLC profile
of each
preparation step.
1: N18 peptide;
2: N6‐N18;
N6 peptide;
5,5′‐dithiobis‐(2‐nitrobenzoic
acid)
(DTNB)‐activated
N6* peptide;
4: dimeric
5:
3: 5,50 -dithiobis-(2-nitrobenzoic
acid)
(DTNB)-activated
N6*
peptide;
4:
dimeric
N6-N18;
5:
final NTD.
final NTD. The elution gradient for these 5 products is 20–35% Buffer B in 0–15 min.
The elution gradient for these 5 products is 20–35% Buffer B in 0–15 min.
While the first disulfide bond should be formed between Cys6 of the first peptide (N6) and
Cys18 of the second peptide (N18), mixing these two peptides together, however, would give rise to
While the first disulfide bond should be formed between Cys6 of the first peptide (N6) and Cys18
three possible products: N6 homodimer, N18 homodimer, and N6‐N18 heterodimer. In order to
of the second peptide (N18), mixing these two peptides together, however, would give rise to three
ensure that only the heterodimer is formed, we took advantage of the thiol‐activating property of
possibleDTNB
products:
N6 homodimer, N18 homodimer, and N6-N18 heterodimer. In order to ensure
(5,5′‐dithiobis‐(2‐nitrobenzoic acid)) and modified Cys6 of N6 peptide with this reagent.
that only
the
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is activated
formed, Cys6
we took
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(N6*)advantage
was mixed with
N18
peptide with unmodified
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and
modified
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of
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this
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Then,
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with
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and
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formed
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theunmodified
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(Figure
2). The
and the product
purity
of each
step were confirmed
by mass
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(Table S1).Cys18 of
form thereaction
first inter-chain
disulfide
bond.
Subsequently,
the second
disulfide
bond (between

N6 peptide and Cys6 of N18 peptide) was formed under the oxidation of iodine (Figure 2). The reaction
and the product purity of each step were confirmed by mass spectrometry (Table S1).
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2.2. nAChR-Inhibitory Activity of NTD

2.2. nAChR‐Inhibitory
of NTD
To determine
whether Activity
the NTD
retains nAChR inhibitory activity of the full-length αD-GeXXA,
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inhibitory
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of the full‐length
αD‐GeXXA,
the functional
ofwhether
the peptide
(5 retains
µM) was
tested
against
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mediated by
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mediated
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different nAChR subtypes heterologously expressed in Xenopus laevis oocytes. While the
currents of human (h) α3β4, α4β4, and α7 nAChRs were not markedly affected, 5 µM NTD reduced
ACh‐evoked currents of human (h) α3β4, α4β4, and α7 nAChRs were not markedly affected, 5 μM
the ACh-evoked
current amplitude at hα3β2, hα4β2, hα9α10, and rodent (r) α1β1εδ nAChRs by
NTD reduced the ACh‐evoked current amplitude at hα3β2, hα4β2, hα9α10, and rodent (r) α1β1εδ
approximately
50%
(Figure 3a,b).50% (Figure 3a,b).
nAChRs
by approximately

3. Inhibition of nAChR subtypes by αD‐GeXXA NTD. (a) Superimposed acetylcholine
Figure 3.Figure
Inhibition
of nAChR subtypes by αD-GeXXA NTD. (a) Superimposed acetylcholine
(ACh)‐evoked currents mediated by hα7, hα9α10 and rα1β1εδ nAChR subtypes in the absence (solid
(ACh)-evoked currents mediated by hα7, hα9α10 and rα1β1εδ nAChR subtypes in the absence (solid
lines) and presence (dashed lines) of 5 μM NTD. (b) Relative current amplitude of different nAChR
lines) andsubtypes
presence
(dashed
lines)
of 5 of
µM
NTD.
(b)sNTD,
Relative
current
amplitudetoofthe
different
nAChR
obtained
in the
presence
5 μM
NTD,
and cNTD
in comparison
absence of
subtypesthe
obtained
in the(mean
presence
of n5=µM
sNTD, and cNTD in
comparison
the absence
of
NTD peptides
± SEM,
3–8).NTD,
(c) Concentration–response
curves
of NTD onto
hα9α10
and
the NTD rα1β1εδ
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(meanexpressed
± SEM, in
n =X.3–8).
Concentration–response
of NTD
on50hα9α10
data point).
The IC
values and
nAChRs
laevis (c)
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(n = 5–8 oocytes for eachcurves
of NTD at expressed
hα9α10 and in
rα1β1εδ
nAChR
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μM andfor
5.88
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respectively.
rα1β1εδ nAChRs
X. laevis
oocytes
(n =are
5–82.33
oocytes
each
point). The IC50 values
of NTD at hα9α10 and rα1β1εδ nAChR subtypes are 2.33 µM and 5.88 µM, respectively.

Concentration‐dependent activity of NTD at hα9α10 nAChR, the subtype most preferred by the
full‐length αD‐GeXXA [18], was determined, giving a half‐maximal inhibitory concentration (IC50) of
Concentration-dependent
of NTD
nAChR,
themonomeric
subtype most
preferred
2.33 μM (Figure 3c, Table activity
1). The potency
of at
thehα9α10
NTD is similar
to the
αD‐GeXXA
CTDby the
(2.02
μM), suggesting
that NTD
also contributes
the high potency
of αD‐GeXXA
(28 nM) at (IC50 )
full-length
αD-GeXXA
[18], was
determined,
giving to
a half-maximal
inhibitory
concentration
inhibiting
the3c,
hα9α10
subtype
[18]. of the NTD is similar to the monomeric αD-GeXXA
of 2.33 µM
(Figure
TablenAChR
1). The
potency
In comparison, the IC50 of NTD at the rodent muscle nAChR subtype was 5.88 μM (Figure 3c,
CTD (2.02 µM), suggesting that NTD also contributes to the high potency of αD-GeXXA (28 nM) at
Table 1). At this subtype, the inhibitory activity of the monomeric CTD was too low to be
inhibitingdetermined
the hα9α10
nAChR subtype [18].
[18]. Therefore, it appears that the NTD part rather than the CTDs of αD‐GeXXA plays a
In comparison,
the
IC50 the
of NTD
the rodent
major role in inhibiting
rodentat
muscle
nAChR.muscle nAChR subtype was 5.88 µM (Figure 3c,

Table 1). At this subtype, the inhibitory activity of the monomeric CTD was too low to be determined [18].
Table 1. Inhibitory
αD‐GeXXA,
NTD,
cNTD of
at hα9α10
and rα1β1εδ
nAChRs.
Therefore, it appears
that theactivity
NTDofpart
ratherCTD,
than
theand
CTDs
αD-GeXXA
plays
a major role in
hα9α10
rα1β1εδ
inhibiting the rodent muscle
nAChR.
Peptide
Table 1.

IC50 (95% CI)
Hill Slope (nH)
IC50 (95% CI)
Hill Slope (nH)
αD‐GeXXA 1
28 nM (22–35)
−1.3
743 nM (606–911)
−1.6
InhibitoryCTD
activity
of
αD-GeXXA, CTD, NTD,
and cNTD‐ at
hα9α10 and‐ rα1β1εδ
1
2
2
2.02 μM (1.82–2.25)
−1.7
NTD
2.33 μM (1.92–2.83)
−0.9
5.88 μM (4.71–7.34)
−1.1
cNTD
2.66 μM (2.15–3.29)
−1.0
3.91 μM (3.35–4.56)rα1β1εδ−1.2
hα9α10

Peptide

αD-GeXXA
CTD 1
NTD
cNTD

1

nAChRs.

1
H ) detected.
[12]; 2(nNot
IC50 (95% CI) Data from
IC50 (95% CI)
Hill Slope

Hill Slope (nH )

−1.3
−1.7
−0.9
−1.0

−1.6
-2
−1.1
−1.2

28 nM (22–35)
2.02 µM (1.82–2.25)
2.33 µM (1.92–2.83)
2.66 µM (2.15–3.29)
1

743 nM (606–911)
-2
5.88 µM (4.71–7.34)
3.91 µM (3.35–4.56)

Data from [12]; 2 Not detected.
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2.3. Preparation and Activity of Truncated NTD
2.3. Preparation
andαD‐GeXXA
Activity of Truncated
NTDto bind onto the top surface of nAChRs, for which there
The dimeric
is postulated
are two possible orientations: with the N‐terminus facing upwards (as shown in Figure 1b), or
The dimeric αD-GeXXA is postulated to bind onto the top surface of nAChRs, for which there are
downwards. This can be distinguished by deleting the N‐terminal extension residues. However, due
two possible orientations: with the N-terminus facing upwards (as shown in Figure 1b), or downwards.
to the complex structure of αD‐GeXXA with 10 disulfide‐bonds per molecule [18], it is difficult to
This can be distinguished by deleting the N-terminal extension residues. However, due to the complex
refold the deletion mutations of dimeric αD‐GeXXA. Given that the NTD peptide has inhibitory
structure of αD-GeXXA with 10 disulfide-bonds per molecule [18], it is difficult to refold the deletion
activity, the binding orientation of the toxin can be determined in the context of NTD.
mutations of dimeric αD-GeXXA. Given that the NTD peptide has inhibitory activity, the binding
Therefore, using the strategy for NTD preparation (Figure 2), we prepared the dimeric short
orientation of the toxin can be determined in the context of NTD.
NTD (sNTD), with the N‐terminal 5 residues (Asp, Val, His, Arg, and Pro) and C‐terminal 2 residues
Therefore, using the strategy for NTD preparation (Figure 2), we prepared the dimeric short NTD
(Ser and Leu) omitted (Figure 4a and Table S1). At 5 μM, sNTD exhibited similar functional activity
(sNTD), with the N-terminal 5 residues (Asp, Val, His, Arg, and Pro) and C-terminal 2 residues (Ser and
to NTD (Figure 3b), indicating that the N‐terminus of this toxin is not required for the interaction
Leu) omitted (Figure 4a and Table S1). At 5 µM, sNTD exhibited similar functional activity to NTD
with nAChRs. This also clarifies that αD‐GeXXA binds to nAChRs with the N‐terminus facing
(Figure 3b), indicating that the N-terminus of this toxin is not required for the interaction with nAChRs.
upwards (Figure 1b).
This also clarifies that αD-GeXXA binds to nAChRs with the N-terminus facing upwards (Figure 1b).

Figure 4. Preparation and functional activity of sNTD, cNTD, and cNTD‐RQ, a mutant of cNTD
Figure 4. Preparation and functional activity of sNTD, cNTD, and cNTD-RQ, a mutant of cNTD
where all the 4 Arg residues are mutated to Gln. (a) Left panel: the topological structure of sNTD
where all the 4 Arg residues are mutated to Gln. (a) Left panel: the topological structure of sNTD
(Cys residues are highlighted in bold). Middle panel: peptide HPLC profile of each sNTD
(Cys residues are highlighted in bold). Middle panel: peptide HPLC profile of each sNTD preparation
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2.4. Preparation and Activity of Cyclic NTD
The feasibility of chemically preparing the active dimeric NTD makes further mutagenesis
study possible, but the multiple‐step
multiple-step procedure (Figure 2) is time‐consuming.
time-consuming. We sought to simplify
this procedure
procedure by
byreducing
reducingthe
thenumber
numberofof
disulfide
bonds,
based
simpler
sNTD
construct.
disulfide
bonds,
based
on on
thethe
simpler
sNTD
construct.
We
We
noticed
the topological
structure
of sNTD
(Figure
4a)the
that
the dimeric
is a tandem
noticed
fromfrom
the topological
structure
of sNTD
(Figure
4a) that
dimeric
sNTD sNTD
is a tandem
repeat
repeat
two sequences,
sNTD sequences,
but by
linked
by one disulfide
in between,
and another
of two of
sNTD
but linked
one disulfide
bond inbond
between,
and another
disulfidedisulfide
bond to
bond
cyclize
two termini.
Therefore,
we removed
the internal
disulfide
by replacing
cyclizetothe
two the
termini.
Therefore,
we removed
the internal
disulfide
bond bond
by replacing
two two
Cys
Cys
residues
residues,
then
linked
two
repeatpeptides
peptideswith
withaaGly
Glyresidue
residue into a
residues
withwith
twotwo
ProPro
residues,
andand
then
linked
thethe
two
repeat
single peptide
chemically
synthesized
singlesingle
polypeptide
chain was
conveniently
cyclized
peptidechain.
chain.This
This
chemically
synthesized
polypeptide
chain
was conveniently
by
oxidizing
the only intra-chain
disulfide disulfide
bond to form
cyclic
(cNTD)
cyclized
by oxidizing
the only intra‐chain
bondato
formNTD
a cyclic
NTD(Figure
(cNTD)4b).
(Figure 4b).
As expected,
expected, cNTD
cNTDretained
retainedthe
thesame
samenAChR
nAChR
inhibitory
profile
full-length
NTD
inhibitory
profile
as as
thethe
full‐length
NTD
andand
the
the
truncated
sNTD
(Figure
3b).also
Wedetermined
also determined
IC50 of
values
at and
hα9α10
and
truncated
sNTD
(Figure
3b). We
the IC50the
values
cNTDofatcNTD
hα9α10
rα1β1εδ
rα1β1εδ
1), are
which
are similar
to of
those
the full-length
(Figure
3c).
nAChRs nAChRs
(Figure 5,(Figure
Table 5,
1),Table
which
similar
to those
the of
full‐length
NTD NTD
(Figure
3c). The
The
comparable
activity
of cNTD
demonstrates
that
artificialPGP
PGP(Pro‐Gly‐Pro)
(Pro-Gly-Pro)motif
motif satisfyingly
satisfyingly
comparable
activity
of cNTD
demonstrates
that
thethe
artificial
adopts the conformation of the two Cys residues linked through an inter-chain
inter‐chain disulfide bond, and
renders
same
conformation
as the
sNTD. sNTD.
Moreover,
the one-step
renders cNTD
cNTDthe
the
same
conformation
asdimeric
the dimeric
Moreover,
the oxidation
one‐step procedure
oxidation
of
cNTD
makes
future
mutational
study
of
this
peptide
easier.
procedure of cNTD makes future mutational study of this peptide easier.

Concentration–responserelationships
relationshipsofofcNTD
cNTDatathα9α10
hα9α10
and
rα1β1εδ
nAChRs
expressed
Figure 5. Concentration–response
and
rα1β1εδ
nAChRs
expressed
in
in laevis
X. laevis
oocytes
5–7 oocytes
for data
eachpoint).
data point).
The
IC50 of
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at and
hα9α10
and
X.
oocytes
(n = (n
5–7= oocytes
for each
The IC50
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cNTDofatcNTD
hα9α10
rα1β1εδ
rα1β1εδsubtypes
nAChR subtypes
are and
2.66 3.91
μM µM,
and 3.91
μM, respectively.
nAChR
are 2.66 µM
respectively.

Then, with
the binding
binding orientation
orientation of
of NTD
NTD clarified,
clarified, we
we investigated
investigated the
the downwards-facing
downwards‐facing
Then,
with the
residues of
of NTD
NTD for
for potential
potential nAChR-binding
nAChR‐binding sites.
sites. Among
Among them,
them, the
the downwards-protruding
downwards‐protruding side
side
residues
chains
of
4
Arg
residues
(two
Arg10
and
Arg13
residues
respectively)
are
prominent
(Figure
1c).
chains of 4 Arg residues (two Arg10 and Arg13 residues respectively) are prominent (Figure 1c). Indeed,
Indeed, replacement
of Argwith
residues
with Gln
residues (cNTD‐RQ)
abolished
inhibition of
replacement
of Arg residues
Gln residues
(cNTD-RQ)
abolished the
inhibitionthe
of ACh-evoked
ACh‐evoked
currents
at
the
hα9α10
nAChR
(Figure
4c),
demonstrating
the
importance
of the 4inArg
currents at the hα9α10 nAChR (Figure 4c), demonstrating the importance of the 4 Arg residues
the
residues
in
the
interaction
with
nAChRs.
interaction with nAChRs.
3. Discussion
3.
Discussion
To date,
date, aa number
number of
of different
different conotoxin
conotoxin families
families have
To
have been
been identified
identified to
to target
target nAChRs,
nAChRs,
including the
the most
most extensively
extensively studied
studied ACh-competitive
ACh‐competitive α-conotoxins
α‐conotoxins [8].
[8]. Other
Other nAChR-targeting
nAChR‐targeting
including
conotoxins include
αB‐,
αC‐,αC-,
and αS‐families,
but their
sites on sites
nAChRs
currently
conotoxins
includethe
theψ‐,ψ-,
αB-,
and αS-families,
butbinding
their binding
on are
nAChRs
are
unknownunknown
[20–23]. [20–23].
In contrast,
another
superfamily
of of
nAChR‐targeting
currently
In contrast,
another
superfamily
nAChR-targetingconotoxin,
conotoxin, namely
namely
αD‐conotoxins, was
wasrecently
recentlyidentified
identified
with
a novel
mechanism
of action
by binding
at the
top
αD-conotoxins,
with
a novel
mechanism
of action
by binding
at the top
surface
surface
of
nAChRs
[18].
Following
this
discovery,
we
further
demonstrate
in
this
study
that
only
the
of nAChRs [18]. Following this discovery, we further demonstrate in this study that only the NTD part
NTD
part of αD‐conotoxin
is a “lid‐covering”
of
αD-conotoxin
GeXXA is aGeXXA
“lid-covering”
antagonistantagonist
of nAChR.of nAChR.
αD‐Conotoxins have been identified from various Conus species, including C. generalis [18], C.
vexillum [24], C. capitaneus, C. mustelinus, and C. miles [25], and possibly make a significant
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αD-Conotoxins have been identified from various Conus species, including C. generalis [18],
C. vexillum [24], C. capitaneus, C. mustelinus, and C. miles [25], and possibly make a significant
contribution to their toxicology. The nanomolar potency of αD-conotoxins at nAChRs [18] suggests
that understanding their mechanism may be valuable for the development of new nAChR inhibitors.
The NTD activity described in this study revealed that, at least for αD-GeXXA, the high potency is a
result of the cooperative nAChR-binding of not only the two CTDs but also the NTD part. In addition,
sNTD retains the potency of NTD at inhibiting nAChRs, which suggests an N-terminal-upward
orientation of the αD-GeXXA when bound to nAChRs (Figure 1b).
The novel “lid-covering” inhibitory mechanism of NTD is clearly different from the typical
nAChR-targeting neurotoxins (α-bungarotoxin and α-conotoxins) that bind to the interface between
the extracellular domains of two adjacent subunits [26,27]. The “lid-covering” inhibition is also distinct
from the pore blockers, as NTD binds to the top surface of the nAChR extracellular domain rather than
within the transmembrane ion channel. Because binding of NTD does not fully seal the entrance of the
receptor-channel pore (Figure S1), we propose that the mechanism of NTD inhibition at nAChRs is not
by simply blocking the cations from entering the channel, but rather by preventing conformational
changes of the extracellular domain that are necessary in linking agonist binding to the opening of the
transmembrane channel [28]. Although it remains to be tested whether the agonist can bind to the
NTD-bound nAChRs, it is likely that the binding of NTD traps the receptor in the resting-closed state.
Another interesting feature of NTD is that it binds only to the N-terminal region of the
nAChRs. Different nAChR subunits have highly homologous sequences and structures, but the
N-terminal region is less conserved (Figure S2). This suggests that “lid-covering” inhibitors would
be advantageous to gain better subtype specificity. Comparing the effects of GeXXA-NTD on
α3β2 vs. α4β2 and α3β4 vs. α4β4 (Figure 3b) suggests that the change of α subunit does not
make much difference to the inhibitory activity of GeXXA-NTD and that GeXXA-NTD mainly
binds to non-α subunits. Similarly, it appears that GeXXA-NTD prefers β2-containing rather than
β4-containing nAChR subtypes (Figure 3b). Consistent with the finding that Arg10 and Arg13 residues
in GeXXA-NTD are critical for nAChR inhibitory activity (Figure 4c), two more acidic residues
(Asp2 and Asp13) are present in the N-terminal α-helix region of the β2 subunit in comparison to β4
subunit (Figure S2). Further study would be required to address whether these acidic residues are
indeed the nAChR-contacting points of GeXXA-NTD.
In summary, by exploring the NTD part of αD-conotoxin GeXXA, we revealed a novel
“lid-covering” inhibitory mechanism for nAChRs. This reinforces the notion that natural neurotoxins
are a valuable reservoir for drug leads or tool reagents. Furthermore, establishment of the activity of the
easily-prepared cyclic NTD in this work paves the way for further rational design for new “lid-covering”
inhibitors with desired subtype specificity, which would be useful for better understanding of the
structure and function of the physiologically fundamental nAChRs.
4. Materials and Methods
4.1. Preparation of NTD and sNTD
To prepare the anti-parallel dimeric NTD, two peptides (N6 and N18) with the sequence of
αD-GeXXA residues Asp1-Leu20 were chemically synthesize (Chinese Peptide, Hangzhou, China).
In peptide N6, the thiol group of Cys6 was not protected, whereas the thiol group of Cys18 was protected
with acetamidomethyl (Acm) group. In peptide N18, the thiol group of Cys6 was protected with Acm,
while the Cys18 side chain was kept free. In both peptides, residue Cys19 was mutated into Ser.
To activate the thiol group of Cys6 in peptide N6, 1 µg/µL of peptide was mixed with 1 mM
5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) (Bio Basic Inc., Markham, ON, Canada) in 150 mM PBS
pH 7.3 and reacted for 15 min at room temperature (20–25 ◦ C) in the dark, then excess DTNB reagent
was removed from the activated N6 (N6*). The first disulfide bond between Cys6 of N6 and Cys18 of
N18 was formed by mixing 0.4 µg/µL N6* and 0.3 µg/µL N18 in 150 mM PBS pH 7.3, and reacting
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for 15 min at room temperature. The dimeric N6-N18 was further oxidized with 2 mM iodine in 75%
acetic acid, 150 mM HCl in the dark for 10 min to form the second disulfide bond between Cys18 of
N6 and Cys6 of N18. The iodine oxidation was quenched with 150 mM ascorbic acid. The synthesized
peptides and the reaction product of each step were purified on a Zobax C18 column (250 × 4.6 mm,
Agilent, Santa Clara, CA, USA) with an acetonitrile elution gradient using an Agilent 1100 HPLC
system. Buffer A for HPLC purification is 0.1% trifluoroacetic acid (TFA) (Merck, Fairfield, OH, USA)
in H2 O and Buffer B is 0.1% TFA in acetonitrile (Duksan Pure Chemicals Co Ltd., Ansan, Korea).
Peptide purity and identity were assessed by Q-trap mass spectrometer (Applied Biosystems,
Foster City, CA, USA), using the scan type of Enhanced MS. The apparatus was equipped with a
TurboIonSpray source and operated in positive ionization mode.
To prepare sNTD, two peptides (sN6 and sN18) with the sequence of αD-GeXXA residues
Cys6-Cys18 were chemically synthesize (Chinese Peptide, Hangzhou, China), and the same strategy
and reaction conditions as NTD preparation were used.
4.2. Preparation of cNTD and cNTD-RQ
To obtain the cyclic NTD, a linear peptide of 27 residues with two Cys residues at both termini was
chemically synthesized (Chinese Peptide, Hangzhou, China). The peptide was dissolved in 400 mM
Arginine, 50 mM Tris·HCl pH 8.1 to 0.075 µg/µL concentration and air-oxidized for 24 h at 4 ◦ C,
and then purified with acetonitrile elution gradient on HPLC C18 column. The linear peptide of
cNTD-RQ was chemically synthesized (GL Biochem Ltd., Shanghai, China) and cyclized under the
same conditions as cNTD.
4.3. Electrophysiological Recordings from nAChRs Exogenously Expressed in Xenopus Oocytes
Oocyte preparation, RNA preparation, and expression of nAChR subunits in Xenopus oocytes
were performed as described previously [18]. All procedures were approved by the University of
Sydney Animal Ethics Committee. Plasmid constructs of rat (α1, β1 and δ), mouse (ε), and human (h)
(α3, α4, α7, α9, α10, β2 and β4) nAChR subunits were linearized for in vitro mRNA synthesis using
mMessage mMachine transcription kit (AMBION, Forster City, CA, USA).
Stage V–VI Xenopus laevis oocytes were defolliculated with collagenase (Worthington Biochemical
Corp., Lakewood, NJ, USA) at room temperature (20–25 ◦ C) for 1 h in OR-2 solution containing
(in mM) 82.5 NaCl, 2 KCl, 1 MgCl2 , and 5 HEPES at pH 7.4. Oocytes were injected with 5 ng cRNA
for hα3β2, α3β4, α4β2, α4β4, α7 or rodent (r) α1β1δε nAChRs and 35 ng cRNA for hα9α10 nAChR
(concentration confirmed spectrophotometrically and by gel electrophoresis) using glass pipettes.
Oocytes were incubated at 18 ◦ C in sterile ND96 solution composed of (in mM) 96 NaCl, 2 KCl, 1 CaCl2 ,
1 MgCl2 , and 5 HEPES at pH 7.4, supplemented with 5% fetal bovine serum, 50 mg/L gentamicin
(GIBCO, Grand Island, NY, USA) and 10,000 U/mL penicillin-streptomycin (GIBCO, Grand Island,
NY, USA).
Membrane currents were recorded from oocytes expressing nAChRs at room temperature,
using a GeneClamp 500B amplifier and pClamp9 software interface (Molecular Devices, Sunnyvale,
CA, USA) in a two-electrode voltage-clamp recording configuration (holding potential −80 mV).
Voltage-recording and current-injecting microelectrodes were pulled from GC150T-7.5 borosilicate
glass (Harvard Apparatus Ltd., Holliston, MA, USA), giving tip resistances of 0.3–1.5 MΩ when filled
with 3 M KCl. Oocytes were perfused with ND96 solution at a rate of 2 mL/min. Oocytes expressing
hα9α10 nAChRs were incubated in 100 µM BAPTA-AM ~3 h before recording and perfused with
ND115 solution containing (in mM): 115 NaCl, 2.5 KCl, 1.8 CaCl2 , and 10 HEPES at pH 7.4. Due to
the Ca2+ permeability of hα9α10 nAChRs, BAPTA-AM incubation was carried out to prevent the
activation of X. laevis oocyte endogenous calcium-activated chloride channels.
Initially, oocytes were briefly washed with bath solution (ND96/ND115) followed by
3 applications of acetylcholine (ACh) at half-maximal effective concentration (EC50 ) values of 6 µM
for hα3β2, hα9α10, and hα4β4 nAChRs, 300 µM for hα3β4, 100 µM ACh for hα7, 3 µM for hα4β2,
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and 1 µM ACh for rα1β1δε nAChRs. Washout with bath solution was done for 3 min between ACh
applications. Oocytes were incubated with peptides for 5 min with the perfusion system turned off,
followed by co-application of ACh and peptide with flowing bath solution. All peptide solutions were
prepared in ND96/ND115 + 0.1% bovine serum albumin. Peak current amplitude evoked by ACh was
measured before and following incubation with peptide in order to determine the effect on specific
nAChR subtype. Concentration-dependent response curves for antagonists were fitted by unweighted
nonlinear regression to the following logistic equation:
H

H

H

Ex = Emax X n /( X n + IC50 n )

(1)

where Ex is the response, X is the antagonist concentration, Emax is the maximal response, nH is the slope
factor, and IC50 is the antagonist concentration giving half-maximal response. Concentration-dependent
response curve and relative current amplitude bar graph data were pooled (n = 3–8 oocytes for each
data point) and represented as means ± standard error of the mean (SEM). The IC50 was determined
from the concentration–response curve and reported with 95% confidence interval (CI). Computation
was performed using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA).
Supplementary Materials: The following are available online at www.mdpi.com/1660-3397/15/6/164/s1.
Table S1: Molecular masses of peptides from NTD and sNTD preparation; Figure S1: Top view of the αD-GeXXA
NTD bound onto the top surface of the human α4β2 nAChR subtype; Figure S2: Sequence alignment of the
extracellular domain of nAChR subunits studied in this work.
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